Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07497607 | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma(REDUCE-30) | recruiting | Phase 2 | 31 | Sara MedekOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05574101 | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | active not recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589049 | Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study(GATEWAY) | not yet recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04848116 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca(Spark2) | active not recruiting | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07492914 | Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | West China HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05420948 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | recruiting | Phase 2 | 30 | University of ChicagoOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05541016 | De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | recruiting | Phase 2 | 455 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07455331 | Flash Radiotherapy for Skin Cancer(LANCE) | not yet recruiting | Phase 2 | 60 | Jules Bordet InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04414540 | Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients | active not recruiting | Phase 2 | 21 | Trisha Wise-DraperOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC(HexAgon-HN) | active not recruiting | Phase 2 / Phase 3 | 410 | Inhibrx Biosciences, IncINDUSTRY | 13 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07573956 | Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies(Radiotherapy) | recruiting | Phase 2 / Phase 3 | 369 | All India Institute of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04403620 | HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 59 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06794372 | [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas(FAPIHN) | recruiting | Phase 2 | 20 | John O. PriorOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05714657 | Shortened Course Adjuvant Radiotherapy Following TORS | active not recruiting | Phase 2 | 104 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07535567 | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma(NimoBenSeq) | not yet recruiting | Phase 2 / Phase 3 | 386 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07559045 | Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 92 | Second Affiliated Hospital of Zunyi Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07408063 | A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)(BeeHive) | recruiting | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07554768 | Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC(RAIN-HNSCC) | not yet recruiting | Phase 2 | 36 | Chen ChunyanOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07419464 | 5-Fluorouracil Response and Optimization STudy (The FROST Trial) | recruiting | Phase 2 | 46 | Washington University School of MedicineOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05108870 | TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers | active not recruiting | Phase 1 / Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05268614 | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 250 | University of FloridaOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07244978 | Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 49 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550972 | Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | enrolling by invitation | Phase 2 | 30 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05893888 | A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers | recruiting | Phase 2 / Phase 3 | 40 | Privo TechnologiesINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04349436 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies(ARTACUS) | active not recruiting | Phase 1 / Phase 2 | 69 | Replimune, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07484724 | A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 280 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545083 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) | not yet recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT03389477 | Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06731933 | Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin | recruiting | Phase 2 | 16 | Stanford UniversityOTHER | 2 | Apr 20, 2026 | clinicaltrials |
| NCT02128906 | Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design | recruiting | Phase 2 | 120 | Christopher WilkeOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07361133 | Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer | not yet recruiting | Phase 2 | 120 | National Cancer Institute, EgyptOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04580771 | A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06669572 | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment | recruiting | Phase 2 | 35 | University of ChicagoOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07519486 | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC(INS-ESCC-CT) | recruiting | Phase 2 | 118 | Sichuan UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07530094 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma(STELLAR01) | recruiting | Phase 2 | 98 | Ning Jiang, M.D./Ph.D.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05576974 | A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) | recruiting | Phase 2 | 120 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06885814 | Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma(N'FORCE) | not yet recruiting | Phase 2 | 131 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT03323463 | Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma | active not recruiting | Phase 2 | 316 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05307939 | A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06097468 | Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San FranciscoOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07423078 | Window of Opportunity in Preserving Laryngeal Function Trial(WOLF) | recruiting | Phase 2 | 87 | Matthew SpectorOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04938609 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | active not recruiting | Phase 2 | 28 | Providence Health & ServicesOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05377905 | Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)(cSCC) | recruiting | Phase 1 / Phase 2 | 48 | Falo, Louis, MDOTHER | 1 | Apr 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 18, 2026source: clinicaltrials